NCT05373446

Evaluation of SSD8432 and Ritonavir in Adult Subjects With COVID-19 Clinical Study

Evaluation of SSD8432 in Combination With Ritonavir in Asymptomatic Infections or Mild/Common Randomized, Double-blind, Safety Study of Efficacy and Safety in Adult Subjects With COVID-19 Placebo-Controlled, Phase II Clinical Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a Randomized, double-blind, Placebo-Controlled, Phase II Clinical Study to evaluate SSD8432 in combination with Ritonavir in asymptomatic infections or mild/common safety study of efficacy and safety in adult subjects with COVID-19.

Detailed description

This is a Randomized, double-blind, Placebo-Controlled, Phase II Clinical Study to evaluate SSD8432 in combination with Ritonavir in asymptomatic infections or mild/common safety study of efficacy and safety in adult subjects with COVID-19. This study planned to enroll 72 subjects, randomly divided into low-dose group, high-dose group and placebo group according to 1:1:1.

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	SSD8432 300mg	SSD8432 300mg in combination with ritonavir 100mg, day1--day5,BID
DRUG	SSD8432 750mg	SSD8432 750mg in combination with ritonavir 100mg, day1--day5,BID
DRUG	SSD8432Placebo	SSD8432Placebo in combination with ritonavir placebo,day1--day5,BID

Timeline

• Start date: 2022-05-20
• Primary completion: 2022-10-31
• Completion: 2023-03-31
• First posted: 2022-05-13
• Last updated: 2022-05-24